Skip to main content

Table 4 Clinical assessments in each group at different time intervals (n = 54)

From: Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial

 

Preop

2 week

6 week

3 months

6 months

1 year

2 years

N

mean ± SD

N

mean ± SD

N

mean ± SD

N

mean ± SD

N

mean ± SD

N

mean ± SD

N

mean ± SD

Harris hip score

 Group ZA

27

60.31 ± 10.49

27

56.23 ± 14.06

27

70.96 ± 13.03a

27

77.93 ± 10.63a

27

83.60 ± 7.52a

27

86.34 ± 7.08a

27

90.18 ± 2.11a

 Group N/S

27

60.88 ± 11.63

27

58.80 ± 10.13

27

71.08 ± 12.26a

27

79.89 ± 9.42a

27

81.50 ± 9.87a

27

85.16 ± 7.28a

27

87.67 ± 5.44a

SF-12(PCS)

 Group ZA

27

27.53 ± 10.13

27

18.96 ± 7.48a

27

28.23 ± 11.35

27

40.01 ± 13.54a

27

48.09 ± 6.95a

27

51.29 ± 4.45a

27

53.69 ± 3.79a

 Group N/S

27

29.16 ± 11.31

27

21.37 ± 8.34a

27

27.79 ± 11.99

27

42.12 ± 10.61a

27

48.96 ± 7.90a

27

50.53 ± 6.95a

27

52.50 ± 4.16a

SF-12(MCS)

 Group ZA

27

57.65 ± 12.57

27

60.87 ± 9.51

27

59.23 ± 10.59

27

60.3 ± 6.86

27

58.85 ± 4.95

27

58.49 ± 4.07

27

58.61 ± 5.98

 Group N/S

27

59.17 ± 11.99

27

60.08 ± 7.29

27

63.72 ± 3.84

27

59.9 ± 4.77

27

55.97 ± 8.34

27

56.96 ± 7.20

27

59.01 ± 4.05

UCLA activity score

 Group ZA

27

3.96 ± 1.16

27

2.56 ± 0.80a

27

3.41 ± 0.97a

27

4.22 ± 0.93

27

4.63 ± 1.15

27

5.74 ± 1.06a

27

7.00 ± 0.90a

 Group N/S

27

4.33 ± 1.59

27

2.56 ± 0.70a

27

3.44 ± 0.97a

27

4.52 ± 0.94

27

4.70 ± 0.95

27

5.52 ± 1.19a

27

6.50 ± 0.74a

  1. Statistically significant difference between ZA and control groups
  2. asignificant difference between each time point and baseline
  3. SD Standard deviation, ZA zoledronic acid, SF short form, PCS physical component summary, MCS mental component summary, N/S normal saline